Die steigende Zahl älterer Menschen und die steigenden Gesundheitsausgaben haben den Bedarf an Krebs-Speicheltestgeräten in Gesundheitseinrichtungen beschleunigt. Die steigende Zahl von Krebspatienten und die zunehmende Prävalenz chronischer Erkrankungen treiben das Marktwachstum zusätzlich voran. Der globale Markt für Krebs-Speicheltestgeräte wächst im Prognosejahr aufgrund der zunehmenden Marktteilnehmer und der Verfügbarkeit fortschrittlicher Produkte. Darüber hinaus forschen und entwickeln Hersteller kontinuierlich an der Markteinführung neuer Produkte.
Vollständigen Bericht abrufen unter https://www.databridgemarketresearch.com/reports/global-cancer-spit-test-device-market
Der globale Markt für Krebs-Spucktestgeräte wird voraussichtlich von 506,76 Millionen US-Dollar im Jahr 2020 auf 1.019,38 Millionen US-Dollar im Jahr 2028 anwachsen und im Prognosezeitraum 2021 bis 2028 mit einer CAGR von 9,7 % wachsen. Die steigende Zahl älterer Menschen und die steigenden Gesundheitsausgaben haben den Bedarf an Krebs-Spucktestgeräten in Gesundheitseinrichtungen beschleunigt. Die steigende Zahl von Krebspatienten und die zunehmende Prävalenz chronischer Erkrankungen treiben das Marktwachstum zusätzlich voran. Der globale Markt für Krebs-Spucktestgeräte wächst im Prognosejahr aufgrund der zunehmenden Marktteilnehmer und der Verfügbarkeit fortschrittlicher Produkte. Darüber hinaus forschen und entwickeln Hersteller kontinuierlich an der Markteinführung neuer Produkte.
Die hohe Prävalenz und Krankheitslast von Krebs weltweit wird die Wachstumsrate des Marktes vorantreiben
Krebs ist die unkontrollierte Ausbreitung abnormer Zellen im Körper. Diese abnormen Zellen werden als Tumorzellen, maligne Zellen oder Krebszellen bezeichnet. Leber-, Magen-, Darm-, Prostata- und Lungenkrebs zählen zu den häufigsten Krebserkrankungen bei Männern, während Schilddrüsen-, Gebärmutterhals-, Lungen-, Darm- und Brustkrebs bei Frauen am häufigsten auftreten. Krebs ist zudem weltweit die zweithäufigste Todesursache. Die zunehmende Verbreitung von Krebserkrankungen erfordert daher fortschrittliche Krebsbehandlungen, wobei Krebsbehandlungen wie Chemotherapien schwerwiegende Risikofaktoren und Nebenwirkungen für den Patienten mit sich bringen. Zu den Nebenwirkungen zählen Anämie, Übelkeit, Erbrechen und verschiedene Infektionskrankheiten.
Berichtsumfang und Marktsegmentierung
Berichtsmetrik
|
Details
|
Prognosezeitraum
|
2021 bis 2028
|
Basisjahr
|
2020
|
Historische Jahre
|
2019 (Anpassbar auf 2013 – 2018)
|
Quantitative Einheiten
|
Umsatz in Millionen USD, Mengen in Einheiten, Preise in USD
|
Abgedeckte Segmente
|
Product Type (Saliva Collection Kits, Fluid Specific Devices, Oral Swab, Bar-Code Labels, Saliva Cryostorage Box, and Others), Site Of Collection (Sub-Mandibular/Sub-Lingual Gland, Parotid Gland, and Minor Salivary Gland), Application (Liver-Lung Cancer, Breast Cancer, Colon And Rectal Cancer, Prostate Cancer, Pancreatic Cancer, Oral Cancer, Thyroid Cancer, Endometrial Cancer, Kidney Cancer, Leukemia, Melanoma, Non-Hodgkin Lymphoma, and Others), Age Group (Adult and Pediatric), Method Of Collection (Passive Drool, Oral Swab, and Others), End User (Hospitals, Diagnostic Laboratories, Oncology Speciality Clinics, Cancer Research Institutes, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others)
|
Countries Covered
|
U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)
|
Market Players Covered
|
DNA Genotek (Canada), Salimetrics, LLC (U.S.), PeriRx (U.S.), Color Health, Inc. (U.S.), SARSTEDT AG. Co. KG (Germany), Miraclean Technology Co.,Ltd. (China), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN, Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), BD (U.S.), Biocartis (Belgium), bioMérieux SA (France), Siemens Healthcare GmbH (Germany), F. Hoffmann-La Roche Ltd (Switzerland), and Oasis Diagnostics Corporation (U.S.) among others
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
Global cancer spit test devices market is categorized into seven notable segments which are based on product type, site of collection, application, age group, method of collection end-user, and distribution channel.
- On the basis of product type, the global cancer spit test devices market is segmented into saliva collection kits, fluid specific devices oral swab, bar-code labels, saliva cryostorage box, and others. In 2021, saliva collection kits segment is expected to dominate the Global cancer spit test devices market with 39.9% market share due to increasing demand for POCT devices and the rising prevalence of cancer patients.
- On the basis of site of collection, the global cancer spit test devices market is segmented into sub-mandibular/sub-lingual gland, parotid gland and minor salivary gland. In 2021, sub-mandibular/sub-lingual gland segment is expected to dominate the global cancer spit test devices market with 63.9% market share because of better patient compliance and increasing healthcare expenditure.
- On the basis of application, the global cancer spit test devices market is segmented into liver-lung cancer, breast cancer, colon and rectal cancer, prostate cancer, pancreatic cancer, oral cancer, thyroid cancer, endometrial cancer, kidney cancer, leukemia, melanoma, non-hodgkin lymphoma In 2021, liver-lung segment is expected to dominate the Global cancer spit test devices market with 26.2% market share because of the rising incidence of liver cirrhosis and chronic diseases.
- On the basis of age group, the global cancer spit test devices market is segmented into adult and pediatrics. In 2021, adult segment is expected to dominate the Global cancer spit test devices market with 81.1% market share because of the rising geriatric population.
- On the basis of method of collection, the global cancer spit test devices market is segmented into passive drool, oral swab and others. In 2021, passive drool segment is expected to dominate the Global cancer spit test devices market with 59.1% market share because it is easy to use and non-invasiveness method.
- On the basis of end user, the global cancer spit test devices market is segmented into hospitals, diagnostic laboratories, oncology specialty clinics, cancer research institutes. In 2021, the hospitals segment is expected to dominate the Global cancer spit test devices market with 40.7% market share because of the rising demand for cancer saliva testing devices in the healthcare sectors.
The hospitals segment will dominate the end user segment of the cancer spit test devices market
The hospitals segment will emerge as the dominating segment end user segment. This is because of the growing number of clinics in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.
- On the basis of distribution channel, the global cancer spit test devices market is segmented into direct tender, retail sales and others. In 2021, direct tender segment is expected to dominate the global cancer spit test devices with 71.9% market share because of the large number of major players in the market.
The direct tender segment will dominate the distribution channel segment of the cancer spit test devices market
The direct tender segment will emerge as the dominating segment under distribution channel. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in market: DNA Genotek (Canada), Salimetrics, LLC (U.S.), PeriRx (U.S.), Color Health, Inc. (U.S.), SARSTEDT AG. Co. KG (Germany), Miraclean Technology Co.,Ltd. (China), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN, Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), BD (U.S.), Biocartis (Belgium), bioMérieux SA (France), Siemens Healthcare GmbH (Germany), F. Hoffmann-La Roche Ltd (Switzerland), and Oasis Diagnostics Corporation (U.S.).
Market Development
- In January 2021, DNA Genotek announced today that the U.S. Food and Drug Administration (FDA) has granted a general use 510(k) clearance for its OrageneDx family of products. This FDA approval has increased the credibility of the company in the market and increased the sales and demand of this product.
- In February 2021, Thermo Fisher Scientific was recognized with Six CMO Leadership Awards. It won across all six categories, including capabilities, compatibility, expertise, quality, reliability and service. This is the second consecutive year Thermo Fisher has received this recognition across all six categories and the eighth time overall that the company has been honored by the CMO Leadership Awards. This has increased the credibility of the company and aids in revenue generation.
Regional Analysis
Geographically, the countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
As per Data Bridge Market Research analysis:
North America is the dominant region in cancer spit test devices market during the forecast period 2021 to 2028
The majority of the market was in North America. This is due to the increasing prevalence of chronic diseases in the region. One of the main potential growth elements thought to be responsible for the prevalence of advanced healthcare infrastructure.
Asia-Pacific is estimated to be the fastest growing region in cancer spit test devices market the forecast period 2021 to 2028
Im Prognosezeitraum wird für den asiatisch-pazifischen Raum ein profitables Wachstum erwartet. Das deutliche Wachstum ist auf steigende Gesundheitskosten zurückzuführen. Der regionale Markt wächst aufgrund der steigenden Zahl von Krebserkrankungen in der Region.
Auswirkungen von COVID-19
Aufgrund steigender Infektionsraten, der Einführung neuer Produkte und des zunehmenden Bedarfs an nicht-invasiven Speicheltests wirkte sich die COVID-19-Epidemie positiv auf die Branche aus. Speichel ist eine praktikable alternative biologische Probe für die COVID-19-Diagnose. Patienten akzeptieren die Speichelentnahme in der Regel, da sie ohne persönliche Schutzausrüstung (PSA) oder die Unterstützung von medizinischem Fachpersonal durchgeführt und von den Patienten selbst durchgeführt werden kann. Die expandierende Branche bietet aufgrund des wachsenden Bedarfs an Diagnosen für COVID-19-infizierte Patienten lukratives Potenzial.
Ausführlichere Informationen zum Markt für Krebs-Spucktestgeräte finden Sie unter: https://www.databridgemarketresearch.com/reports/global-cancer-spit-test-device-market
